Key Factors Driving the Growth of the Non-small Cell Lung Cancer Market\u00a0<\/p>\n
Rising NSCLC Incidence: Non-small cell lung cancer continues to represent a significant healthcare burden in the United States, although its incidence is showing signs of stabilization. This trend reflects the impact of sustained tobacco control efforts, which have contributed to a gradual decline in overall lung cancer rates, while broader adoption of low-dose CT screening and increased incidental detection through routine imaging have led to more diagnoses at earlier stages. In 2025, the US recorded approximately 203,000 incident NSCLC cases, a figure projected to increase modestly to around 205,000 cases by 2036.
\n Rising Opportunities in EGFR NSCLC Therapies: In EGFR-mutated NSCLC, where Tagrisso continues to dominate the market, Rybrevant is steadily strengthening its position. The J&J therapy has expanded into the broader first-line EGFR-mutated NSCLC setting through its combination with the oral EGFR-TKI Lazcluze. Additionally, the company is pursuing the launch of a subcutaneous (SC) formulation of Rybrevant to further enhance patient convenience and treatment accessibility.
\n The Untapped Potential of Front-Line NSCLC Treatment: Front-line NSCLC represents a large market, currently only being dominated by anti-PD1 drugs and anti-PD-1 + CTx combination, leaving a significant opportunity for therapy beyond anti-PD1 to deliver higher clinical benefit.\u00a0
\n Robust NSCLC Clinical Trial Activities: The NSCLC clinical trial landscape is robust with various candidates in late stage of development, including BMS-986504 + Pembrolizumab (BMS), Iza-bren (izalontamab brengitecan) (SystImmune and Bristol Myers Squibb), Neladalkib (NVL-655) (Nuvalent), PF-08046054 (SGN-PDL1V) (Pfizer), Telisotuzumab adizutecan, Temab-A (ABBV-400) (AbbVie), Daraxonrasib (RMC-6236) (Revolution Medicines), ZEJULA (niraparib) (GSK), Rilvegostomig (AZD2936) (AstraZeneca\/Compugen), Pumitamig (BNT327\/PM8002) (BioNTech\/BMS), CAN-2409 (aglatimagene besadenovec) (Candel Therapeutics), and other.<\/p>\n
Sadaf Javed, Functional Head, Forecasting at DelveInsight, said that the total market size of KRAS-mutated NSCLC in the US was nearly USD 2.23 billion in 2025. The most frequent KRAS variant in NSCLC is G12C. KRAS-mutated NSCLC represents a rapidly evolving and highly competitive market across 1L and 2L+ settings, driven by the shift from first-generation monotherapies to next-generation, combination-based strategies. In the 2L+ settings, approved agents such as LUMAKRAS (2021) and KRAZATI (2023) established the KRAS G12C class, with KRAZATI demonstrating slightly stronger competitive positioning.<\/p>\n
Non-small Cell Lung Cancer Market Analysis<\/p>\n
Real-world treatment patterns in non-small cell lung cancer have evolved considerably, with a clear transition from conventional systemic therapies to targeted treatments and immunotherapies, which now represent the primary drivers of therapeutic advancement.\u00a0
\n However, a substantial proportion of NSCLC patients remain ineligible for targeted therapies due to the absence of actionable mutations. In these patients, PD-L1\u2013directed therapies play a central role, with Merck’s KEYTRUDA, particularly in combination with platinum-based chemotherapy, continuing to serve as the standard first-line treatment irrespective of PD-L1 expression levels.
\n A major challenge in the immunotherapy landscape is the development of acquired resistance to PD-1\/PD-L1 inhibitors. As resistance emerges, many patients lose the clinical benefit of these agents and are often left with chemotherapy, which may offer limited efficacy and considerable toxicity.\u00a0
\n This significant unmet need has prompted extensive research into novel therapeutic agents and combination regimens for patients with advanced NSCLC who have progressed following immunotherapy.
\n Among molecularly defined NSCLC subtypes, EGFR exon 20 insertion mutations have attracted significant attention in recent years, resulting in an increasingly competitive treatment landscape.\u00a0
\n Beyond these alterations, uncommon EGFR mutations, including G719X, S768I, and PACC variants, are emerging as important areas of clinical development and represent the next frontier for targeted therapies in EGFR-mutated NSCLC.
\n In ALK-positive NSCLC, ALECENSA and ALUNBRIG have become the preferred first-line tyrosine kinase inhibitors (TKIs), with ALECENSA maintaining a dominant position due to its broader clinical adoption. Before the introduction of these next-generation agents, XALKORI was the primary treatment option for ALK-rearranged disease.
\n KRAS-mutated NSCLC has also witnessed substantial progress, particularly for the KRAS G12C subtype, which represents the most common KRAS alteration in NSCLC. As multiple therapies now target this mutation, the G12C segment is becoming increasingly crowded and competitive.\u00a0
\n Future growth opportunities are expected to arise from expanding treatment options in relapsed\/refractory settings and advancing KRAS-targeted therapies into first-line treatment.
\n The treatment landscape for rare NSCLC biomarkers remains less well-defined due to the low prevalence of these alterations and the limited availability of late-stage clinical evidence.\u00a0
\n Nevertheless, significant advancements have been achieved for rare molecular subsets such as ROS1 rearrangements, HER2 mutations, RET fusions, and NTRK gene fusions, leading to improved therapeutic options for these patient populations.
\n Despite remarkable progress in precision oncology and immunotherapy, early-stage NSCLC (Stages I\u2013III) continues to represent a significant area of unmet need. Surgical resection followed by adjuvant platinum-based chemotherapy remains the standard of care but provides only modest survival benefits while exposing patients to substantial toxicity.\u00a0
\n Although immunotherapeutic approaches, including PD-1\/PD-L1 inhibitors and neoadjuvant chemo-immunotherapy regimens, have demonstrated encouraging improvements in event-free survival and pathological response rates, their integration into routine clinical practice is still evolving, with challenges related to accessibility, patient selection, and treatment personalization.
\n The dynamics of the NSCLC market are anticipated to change in the coming years owing to the improvement in the rise in healthcare spending across the world. Some of the key players in the pipeline include Bristol Myers Squibb, SystImmune, Nuvalent, Pfizer, AbbVie, Revolution Medicines, GSK, AstraZeneca, Compugen, BioNTech, Candel Therapeutics, OncoC4, Incyte, Macrogenics, Iovance Biotherapeutics, Hoffmann-La Roche, Genentech, Regeneron Pharmaceuticals, and others are involved in developing drugs for NSCLC.<\/p>\n
Non-small Cell Lung Cancer Competitive Landscape<\/p>\n
Some of the NSCLC drugs under late stage of development include BMS-986504 + Pembrolizumab (BMS), Iza-bren (izalontamab brengitecan) (SystImmune and Bristol Myers Squibb), Neladalkib (NVL-655) (Nuvalent), PF-08046054 (SGN-PDL1V) (Pfizer), Telisotuzumab adizutecan, Temab-A (ABBV-400) (AbbVie), Daraxonrasib (RMC-6236) (Revolution Medicines), ZEJULA (niraparib) (GSK), Rilvegostomig (AZD2936) (AstraZeneca\/Compugen), Pumitamig (BNT327\/PM8002) (BioNTech\/BMS), CAN-2409 (aglatimagene besadenovec) (Candel Therapeutics), Gotistobart (BNT316, ONC-392) (OncoC4\/BioNTech), ZYNYZ (retifanlimab-dlwr, INCMGA00012) (Incyte\/Macrogenics), LN-145 (Iovance Biotherapeutics), Divarasib (GDC-6036) (Hoffmann-La Roche\/Genentech), Fianlimab (REGN3767) (Regeneron Pharmaceuticals), Sacituzumab tirumotecan (MK-2870\/SKB264) (Merck and Kelun-Biotech), Eftilagimod alpha (Immutep), Intismeran autogene (mRNA-4157\/ V940) (Moderna Therapeutics and Merck), Plinabulin (BeyondSpring), Zipalertinib (Cullinan Oncology\/Taiho Pharma), Olomorasib (Eli Lilly and Company), Ceralasertib (AstraZeneca), TEDOPI OSE (Immuno-therapeutics), Sigvotatug vedotin (Pfizer), ANKTIVA (ImmunityBio), Pyrotinib (Jiangsu HengRui Medicine), Volrustomig (AstraZeneca), TRODELVY (sacituzumab govitecan) (Gilead Sciences), Domvanalimab + Combination Therapies (Arcus Biosciences\/Gilead Sciences), OPDUALAG (nivolumab and relatlimab) (Bristol Myers Squibb), Calderasib (MK-1084) [Merck, Otsuka Pharmaceutical (Taiho, and Astex Pharmaceuticals)], Firmonertinib (ArriVent BioPharma\/Shanghai Allist Pharmaceuticals), IBI363 (Innovent Biologics and Takeda Pharmaceutical), Vebreltinib (APL-101) (Apollomics and Avistone Biotechnology), and others.<\/p>\n
Immutep’s Eftilagimod alpha is a recombinant soluble protein composed of a dimeric form of LAG-3 that has been engineered to circulate freely rather than remain attached to the cell surface. As a first-in-class activator of antigen-presenting cells (APCs), it enhances immune system activity and has demonstrated the ability to generate durable immune responses in cancer patients. The therapy can be administered at lower doses as an adjuvant to cancer vaccines or at higher doses to achieve broader systemic activation of APCs.<\/p>\n
Nuvalent’s Neladalkib is an advanced, brain-penetrant ALK inhibitor with high selectivity, developed to effectively target ALK resistance mutations while minimizing central nervous system toxicities associated with TRK inhibition. Created by Nuvalent for the treatment of ALK-driven malignancies, the therapy is designed to address resistance mechanisms and offer improved tolerability. It is currently undergoing clinical investigation.<\/p>\n
Revolution Medicines’ Daraxonrasib (RMC-6236) is an orally administered, multi-selective inhibitor that directly targets the active RAS(ON) state, enabling broad applicability across cancers driven by RAS mutations. By preventing activated RAS proteins from interacting with downstream signaling effectors, it disrupts key pathways responsible for tumor growth and survival. The drug is active against several oncogenic RAS variants, including G12X, G13X, and Q61X mutations, which are frequently observed in cancers such as non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC), and colorectal cancer (CRC).<\/p>\n
Iovance Biotherapeutics’ LN-145 is an autologous tumor-infiltrating lymphocyte (TIL) therapy that harnesses a patient’s own immune cells to combat cancer. The treatment is produced by isolating T cells from a patient’s tumor tissue and expanding them outside the body before reinfusion. A related product, LN-145-S1, is manufactured through an enhanced process that selectively enriches a specific subset of T cells, potentially improving therapeutic activity.<\/p>\n
The anticipated launch of these emerging therapies are poised to transform the non-small cell lung cancer market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the non-small cell lung cancer market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.<\/p>\n
Discover more about non-small cell lung cancer PD-L1 inhibitors competitors 2026 @ Non-small Cell Lung Cancer Therapeutics Market<\/a><\/p>\n Recent Developments in the Non-small Cell Lung Cancer Market<\/p>\n In June 2026, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced the online publication of translational research findings in the international journal Cancer Cell, highlighting the use of sacituzumab tirumotecan in combination with osimertinib as a first-line therapy for patients with advanced EGFR-mutant non-small cell lung cancer (NSCLC). What is Non-small Cell Lung Cancer?<\/p>\n Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for approximately 85% of all lung cancer cases. It is a heterogeneous group of malignancies that originate from the epithelial cells of the lung and includes several histological subtypes, primarily adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. NSCLC typically grows and spreads more slowly than small cell lung cancer (SCLC), although disease progression can vary depending on the tumor subtype and molecular characteristics. Major risk factors include tobacco smoking, exposure to environmental carcinogens such as radon and asbestos, air pollution, and certain genetic predispositions. Advances in molecular diagnostics have identified key genetic alterations, including mutations in EGFR, ALK, ROS1, KRAS, and other oncogenic drivers, enabling the development of targeted therapies and immunotherapies that have significantly improved treatment outcomes for patients with advanced disease.<\/p>\n Non-small Cell Lung Cancer Epidemiology Segmentation<\/p>\n The non-small cell lung cancer epidemiology section provides insights into the historical and current non-small cell lung cancer patient pool and forecasted trends for the leading markets. Among the 7MM, the US accounted for the highest incident cases of NSCLC in 2025. This was followed by Japan, whereas the least number of cases were accounted by Spain.<\/p>\n The non-small cell lung cancer treatment market report proffers epidemiological analysis for the study period 2022\u20132036 in the leading markets, segmented into:<\/p>\n Total Incident Cases of NSCLC\u00a0 Non-small Cell Lung Cancer Market Report Metrics<\/p>\n Details<\/p>\n Study Period<\/p>\n 2022\u20132036<\/p>\n Coverage<\/p>\n 7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].<\/p>\n Non-small Cell Lung Cancer Market CAGR<\/p>\n 6.6\u00a0%<\/p>\n Non-small Cell Lung Cancer Market Size in 2025<\/p>\n USD 33 Billion<\/p>\n Key Non-small Cell Lung Cancer Companies<\/p>\n SystImmune, Bristol Myers Squibb, Nuvalent, AbbVie, Revolution Medicines, GSK, Compugen, BioNTech, Candel Therapeutics, OncoC4, BioNTech, Incyte, Macrogenics, Iovance Biotherapeutics, Hoffmann-La Roche, Genentech, Regeneron Pharmaceuticals, Kelun-Biotech, Immutep, Moderna Therapeutics, BeyondSpring, Cullinan Oncology, Eli Lilly and Company, OSE Immuno-therapeutics, Pfizer, ImmunityBio, Jiangsu HengRui Medicine, AstraZeneca, Arcus Biosciences, Gilead Sciences, Merck, Otsuka Pharmaceutical (Taiho, and Astex Pharmaceuticals), ArriVent BioPharma, Shanghai Allist Pharmaceuticals, Innovent Biologics, Takeda Pharmaceutical, Apollomics, Avistone Biotechnology, Boehringer Ingelheim, Hansoh Pharma, Dizal (Jiangsu) Pharmaceutical, Johnson & Johnson Innovative Medicine (Janssen), and others<\/p>\n Key Non-small Cell Lung Cancer Therapies<\/p>\n Iza-bren (izalontamab brengitecan), BMS-986504 + Pembrolizumab, Neladalkib (NVL-655), PF-08046054 (SGN-PDL1V), Telisotuzumab adizutecan, Temab-A (ABBV-400), Daraxonrasib (RMC-6236), ZEJULA (niraparib), Rilvegostomig (AZD2936), Pumitamig (BNT327\/PM8002), CAN-2409 (aglatimagene besadenovec), Gotistobart (BNT316, ONC-392), ZYNYZ (retifanlimab-dlwr, INCMGA00012), LN-145, Divarasib (GDC-6036), Fianlimab (REGN3767), Sacituzumab tirumotecan (MK-2870\/SKB264), Eftilagimod alpha, Intismeran autogene (mRNA-4157\/V940), Plinabulin, Zipalertinib, Olomorasib, Ceralasertib, TEDOPI, Sigvotatug vedotin, ANKTIVA, Pyrotinib, Volrustomig, TRODELVY (sacituzumab govitecan), Domvanalimab + Combination Therapies, OPDUALAG (nivolumab and relatlimab), Calderasib (MK-1084), Firmonertinib, IBI363, Vebreltinib (APL-101), TAGRISSO, GILOTRIF\/GIOTRIF, VIZIMPRO, EXKIVITY, AUMSEQA, ZEGFROVY, RYBREVANT, DATROWAY, PORTRAZZA, KEYTRUDA, OPDIVO and others<\/p>\n Scope of the Non-small Cell Lung Cancer Market Report<\/p>\n Non-small Cell Lung Cancer Patient Population Forecast Download the report to understand the first-line treatment of advanced non-small cell lung cancer @ Non-small Cell Lung Cancer Pharmaceutical Company<\/a><\/p>\n Table of Contents<\/p>\n 1<\/p>\n Non-small Cell Lung Cancer Market Key Insights<\/p>\n 2<\/p>\n Non-small Cell Lung Cancer Market Report Introduction<\/p>\n 3<\/p>\n Key Highlights<\/p>\n 4<\/p>\n Executive Summary<\/p>\n 5<\/p>\n Key Events<\/p>\n 6<\/p>\n Epidemiology and Market Forecast Methodology of NSCLC<\/p>\n 7<\/p>\n NSCLC Market Overview at a Glance<\/p>\n 7.1<\/p>\n Emerging Landscape Analysis in the 7MM (by Phase)<\/p>\n 7.2<\/p>\n Market Share of NSCLC by Biomarker (%) in the 7MM in 2025<\/p>\n 7.3<\/p>\n Market Share of NSCLC by Biomarker (%) in the 7MM in 2036<\/p>\n 8<\/p>\n Disease Background and Overview of NSCLC<\/p>\n 8.1<\/p>\n Introduction<\/p>\n 8.2<\/p>\n Disease Biology: NSCLC<\/p>\n 8.3<\/p>\n Diagnosis<\/p>\n 9<\/p>\n Current Treatment Practices: NSCLC<\/p>\n 9.1<\/p>\n Treatment Algorithm<\/p>\n 9.2<\/p>\n Treatment Guidelines and Recommendations for NSCLC<\/p>\n 10<\/p>\n Epidemiology and Patient Population<\/p>\n 10.1<\/p>\n Key Findings<\/p>\n 10.2<\/p>\n Assumptions and Rationale<\/p>\n 10.3<\/p>\n Total Incident Cases of NSCLC in the 7MM\u00a0<\/p>\n 10.4<\/p>\n United States<\/p>\n 10.4.1<\/p>\n Total Incident Cases of NSCLC in the United States<\/p>\n 10.4.2<\/p>\n Gender-specific Cases of NSCLC in the United States<\/p>\n 10.4.3<\/p>\n Age-specific Cases of NSCLC in the United States<\/p>\n 10.4.4<\/p>\n Total Incident Cases of NSCLC by Histology in the United States<\/p>\n 10.4.5<\/p>\n Total Incident Cases of NSCLC by Stage in the United States<\/p>\n 10.4.6<\/p>\n Total Cases of NSCLC by Genetic Mutations\/Biomarkers in the United States<\/p>\n 10.4.7<\/p>\n Patient Seeking Treatment for NSCLC in the United States<\/p>\n 10.4.8<\/p>\n Line-wise Treated Cases of NSCLC in the United States<\/p>\n 10.5<\/p>\n EU4 and the UK<\/p>\n 10.6<\/p>\n Japan<\/p>\n 11<\/p>\n Patient Journey<\/p>\n 12<\/p>\n Key Endpoints in NSCLC<\/p>\n 13<\/p>\n Marketed NSCLC Therapies<\/p>\n 13.1<\/p>\n Competitive Landscape<\/p>\n 13.1.1<\/p>\n Regulatory Approval History Across the 7MM<\/p>\n 13.2<\/p>\n EGFR Mutations<\/p>\n 13.2.1<\/p>\n AUMSEQA (Aumolertinib): Jiangsu Hansoh Pharmaceutical<\/p>\n 13.2.1.1<\/p>\n Product Description<\/p>\n 13.2.1.2<\/p>\n Regulatory Milestones<\/p>\n 13.2.1.3<\/p>\n Other Developmental Activity<\/p>\n 13.2.1.4<\/p>\n Summary of Pivotal Clinical Trial<\/p>\n 13.2.2<\/p>\n VIZIMPRO (Dacomitinib): Pfizer<\/p>\n 13.2.3<\/p>\n GILOTRIF\/GIOTRIF (Afatinib maleate): Boehringer Ingelheim<\/p>\n 13.2.4<\/p>\n TAGRISSO (Osimertinib): AstraZeneca<\/p>\n 13.2.5<\/p>\n PORTRAZZA (Necitumumab): Eli Lilly and Company<\/p>\n 13.2.6<\/p>\n RYBREVANT (Amivantamab) \u00b1 LAZCLUZE (Lazertinib): Johnson & Johnson Innovative Medicine\/Yuhan Corporation<\/p>\n 13.2.7<\/p>\n ZEGFROVY (Sunvozertinib): Dizal Pharmaceutical<\/p>\n 13.2.8<\/p>\n DATROWAY (Datopotamab Deruxtecan): Daiichi Sankyo\/AstraZeneca<\/p>\n 13.3<\/p>\n PD-1 Inhibitors<\/p>\n 13.3.1<\/p>\n OPDIVO (Nivolumab): Bristol Myers Squibb\/Ono Pharmaceutical<\/p>\n 13.3.2<\/p>\n KEYTRUDA (Pembrolizumab): Merck<\/p>\n 13.3.3<\/p>\n LIBTAYO (Cemiplimab): Regeneron\/Sanofi<\/p>\n 13.3.4<\/p>\n TEVIMBRA (Tislelizumab): BeiGene<\/p>\n 13.3.5<\/p>\n IMFINZI (Durvalumab) + IMJUDO (Tremelimumab): AstraZeneca<\/p>\n 13.3.6<\/p>\n CEJEMLY (Sugemalimab): CStone Pharmaceuticals<\/p>\n 13.3.7<\/p>\n IMFINZI (Durvalumab): AstraZeneca<\/p>\n 13.3.8<\/p>\n TECENTRIQ (Atezolizumab): Genentech\/Roche<\/p>\n 13.4<\/p>\n Other Mutations<\/p>\n 13.4.1<\/p>\n LORBRENA\/LORVIQUA (Lorlatinib): Pfizer<\/p>\n 13.4.2<\/p>\n ENSACOVE (Ensartinib): Betta Pharmaceuticals\/Xcovery<\/p>\n 13.4.3<\/p>\n ALUNBRIG (Brigatinib): Takeda Pharmaceuticals<\/p>\n 13.4.4<\/p>\n AUGTYRO (Repotrectinib): BMS<\/p>\n 13.4.5<\/p>\n ALECENSA (Alectinib): Roche\/Chugai Pharmaceutical<\/p>\n 13.4.6<\/p>\n ROZLYTREK (Entrectinib): Roche (Genentech)<\/p>\n 13.4.7<\/p>\n IBTROZI (Taletrectinib): Nuvation Bio<\/p>\n 13.4.8<\/p>\n GAVRETO (Pralsetinib): Blueprint Medicines\/Rigel Pharmaceuticals<\/p>\n 13.4.9<\/p>\n RETEVMO\/RETSEVMO (Selpercatinib): Eli Lilly and Company<\/p>\n 13.4.10<\/p>\n TEPMETKO (Tepotinib): EMD Serono (Merck KGaA)<\/p>\n 13.4.11<\/p>\n HAIYITAN (Gumarontinib): Haihe Biopharma and Taiho Pharmaceutical<\/p>\n 13.4.12<\/p>\n TABRECTA (Capmatinib): Novartis<\/p>\n 13.4.13<\/p>\n LUMAKRAS\/LUMYKRAS (Sotorasib): Amgen<\/p>\n 13.4.14<\/p>\n KRAZATI (Adagrasib): BMS<\/p>\n 13.4.15<\/p>\n ENHERTU (Trastuzumab deruxtecan): Daiichi Sankyo \/AstraZeneca<\/p>\n 13.4.16<\/p>\n TAFINLAR (Dabrafenib) + MEKINIST (Trametinib): Novartis<\/p>\n 13.4.17<\/p>\n BRAFTOVI (Encorafenib) + MEKTOVI (Binimetinib): Pfizer\/Pierre Fabre<\/p>\n 13.4.18<\/p>\n VITRAKVI (Larotrectinib): Bayer<\/p>\n 13.4.19<\/p>\n EMRELIS (Telisotuzumab vedotin-tllv): AbbVie<\/p>\n 13.4.20<\/p>\n BIZENGRI (Zenocutuzumab): Merus and Partner Therapeutics<\/p>\n 13.4.21<\/p>\n HYRNUO (Sevabertinib): Bayer<\/p>\n 13.4.22<\/p>\n HERNEXEOS (Zongertinib): Boehringer Ingelheim<\/p>\n 14<\/p>\n Emerging NSCLC Therapies<\/p>\n 14.1<\/p>\n Competitive Landscape<\/p>\n 14.2<\/p>\n Ateganosine: MAIA Biotechnology<\/p>\n 14.2.1<\/p>\n Product Description<\/p>\n 14.2.2<\/p>\n Other Developmental Activities<\/p>\n 14.2.3<\/p>\n Clinical Development<\/p>\n 14.2.3.1<\/p>\n Clinical Trials Information<\/p>\n 14.2.4<\/p>\n Safety and Efficacy<\/p>\n 14.3<\/p>\n BMS-986504 + Pembrolizumab: Bristol-Myers Squibb<\/p>\n 14.4<\/p>\n Iza-bren (izalontamab brengitecan): SystImmune and Bristol Myers Squibb<\/p>\n 14.5<\/p>\n Neladalkib (NVL-655): Nuvalent<\/p>\n 14.6<\/p>\n PF-08046054 (SGN-PDL1V): Pfizer<\/p>\n 14.7<\/p>\n Telisotuzumab adizutecan, Temab-A (ABBV-400): AbbVie<\/p>\n 14.8<\/p>\n Daraxonrasib (RMC-6236): Revolution Medicines<\/p>\n 14.9<\/p>\n ZEJULA (niraparib): GlaxoSmithKline<\/p>\n 14.10<\/p>\n Rilvegostomig (AZD2936): AstraZeneca\/Compugen<\/p>\n 14.11<\/p>\n Pumitamig (BNT327\/PM8002): BioNTech\/Bristol Myers Squibb<\/p>\n 14.12<\/p>\n CAN-2409 (aglatimagene besadenovec): Candel Therapeutics<\/p>\n 14.13<\/p>\n Gotistobart (BNT316): OncoC4\/BioNTech<\/p>\n 14.14<\/p>\n ZYNYZ (retifanlimab-dlwr): Incyte\/Macrogenics<\/p>\n 14.15<\/p>\n LN-145: Iovance Biotherapeutics<\/p>\n 14.16<\/p>\n Divarasib (GDC-6036): Hoffmann-La Roche\/Genentech<\/p>\n 14.17<\/p>\n Fianlimab (REGN3767): Regeneron Pharmaceuticals<\/p>\n 14.18<\/p>\n Sacituzumab Tirumotecan (MK-2870): Merck and Kelun-Biotech<\/p>\n 14.19<\/p>\n Eftilagimod alpha (Efti, IMP321): Immutep<\/p>\n 14.20<\/p>\n Intismeran autogene (mRNA-4157\/V940): Moderna Therapeutics and Merck Sharp & Dohme<\/p>\n 14.21<\/p>\n Plinabulin: BeyondSpring<\/p>\n 14.22<\/p>\n Zipalertinib (CLN-081): Cullinan Therapeutics and Taiho Pharma<\/p>\n 14.24<\/p>\n Olomorasib (LY3537982): Eli Lilly and Company<\/p>\n 14.25<\/p>\n Ceralasertib (AZD6738): AstraZeneca<\/p>\n 14.26<\/p>\n TEDOPI (OSE2101): OSE Immunotherapeutics<\/p>\n 14.27<\/p>\n Sigvotatug Vedotin (PF08046047, SGN-B6A): Pfizer<\/p>\n 14.28<\/p>\n ANKTIVA (N-803, nogapendekin alfa inbakicept-pmln): ImmunityBio<\/p>\n 14.29<\/p>\n Pyrotinib: Jiangsu HengRui Medicine<\/p>\n 14.30<\/p>\n Volrustomig (MEDI5752): AstraZeneca<\/p>\n 14.31<\/p>\n TRODELVY (sacituzumab govitecan): Gilead Sciences<\/p>\n 14.32<\/p>\n Domvanalimab + Combination Therapies: Arcus Biosciences and Gilead Sciences<\/p>\n 14.33<\/p>\n OPDUALAG (nivolumab and relatlimab): Bristol-Myers Squibb<\/p>\n 14.34<\/p>\n Calderasib (MK-1084): Merck, Otsuka Pharmaceutical (Taiho, and Astex Pharmaceuticals)<\/p>\n 14.35<\/p>\n Firmonertinib: ArriVent BioPharma and Shanghai Allist Pharmaceuticals<\/p>\n 14.36<\/p>\n Livmoniplimab (ARGX-115): AbbVie<\/p>\n 14.37<\/p>\n IBI363: Innovent Biologics and Takeda Pharmaceutical<\/p>\n 14.38<\/p>\n Ivonescimab (AK112): Akeso Bio and Summit Therapeutics<\/p>\n 14.39<\/p>\n Vebreltinib (APL-101): Apollomics and Avistone Biotechnology<\/p>\n 14.4<\/p>\n Zidesamtinib (NVL-520): Nuvalent<\/p>\n 15<\/p>\n Phase II Emerging Drugs Under Development<\/p>\n 16<\/p>\n NSCLC: 7MM Market Analysis<\/p>\n 16.1<\/p>\n Key Findings<\/p>\n 16.2<\/p>\n Total Market Size of NSCLC by Country in the 7MM\u00a0<\/p>\n 16.3<\/p>\n Total Market Size of NSCLC by Biomarker in the 7MM\u00a0<\/p>\n 16.4<\/p>\n Market Outlook of NSCLC<\/p>\n 16.4.1<\/p>\n 7MM Market Dynamics Overview of NSCLC<\/p>\n 16.4.1.1<\/p>\n PD-L1 Expression<\/p>\n 16.4.1.2<\/p>\n EGFR Mutation<\/p>\n 16.4.1.3<\/p>\n ALK Mutation<\/p>\n 16.4.1.4<\/p>\n KRAS Mutation<\/p>\n 16.4.1.5<\/p>\n BRAF Mutation<\/p>\n 16.4.1.6<\/p>\n MET<\/p>\n 16.4.1.7<\/p>\n Others Emerging Biomarkers<\/p>\n 16.5<\/p>\n Key Market Forecast Assumptions<\/p>\n 16.5.1<\/p>\n PD-L1 Expression<\/p>\n 16.5.2<\/p>\n EGFR NSCLC<\/p>\n 16.5.3<\/p>\n ALK NSCLC<\/p>\n 16.5.4<\/p>\n KRAS NSCLC<\/p>\n 16.5.5<\/p>\n ROS-1 NSCLC<\/p>\n 16.5.6<\/p>\n HER2 NSCLC<\/p>\n 16.5.7<\/p>\n BRAF NSCLC<\/p>\n 16.5.8<\/p>\n C-Met NSCLC<\/p>\n 16.5.9<\/p>\n RET NSCLC<\/p>\n 16.5.10<\/p>\n NTRK NSCLC<\/p>\n 16.5.11<\/p>\n NRG1 Fusion NSCLC<\/p>\n 16.6<\/p>\n The United States NSCLC Market<\/p>\n 16.7<\/p>\n EU4 and the UK NSCLC Market<\/p>\n 16.8<\/p>\n Japan NSCLC Market<\/p>\n 17<\/p>\n Unmet Needs of NSCLC<\/p>\n 18<\/p>\n SWOT Analysis of NSCLC<\/p>\n 19<\/p>\n KOL Views of NSCLC<\/p>\n 20<\/p>\n Market Access and Reimbursement of NSCLC<\/p>\n 21<\/p>\n Bibliography<\/p>\n 22<\/p>\n NSCLC Market Report Methodology<\/p>\n Related Reports<\/p>\n Non-small Cell Lung Cancer Clinical Trial Analysis\u00a0<\/a><\/p>\n Non-small Cell Lung Cancer Pipeline Insight \u2013 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key non-small cell lung cancer companies, including ArriVent BioPharma, iTeos Therapeutics, GSK, Incyte, Macrogenics, AstraZeneca, Hutchison MediPharma, Hoffmann-La Roche, Genentech, AnaptysBio, Shanghai Henlius Biotech, Otsuka Pharmaceutical, Bristol-Myers Squibb, OSE Immunotherapeutics, Arcus Biosciences, Gilead Sciences, Pfizer, Cullinan Oncology, Taiho Pharma, ImmunityBio, Jiangsu Hansoh Pharmaceutical, Daiichi Sankyo, Boehringer Ingelheim, Moderna Therapeutics, Merck Sharp & Dohme, Eli Lilly and Company, BeyondSpring, Immutep, Genmab, Imugene, Dizal Pharmaceutical, Regeneron Pharmaceuticals, AbbVie, Candel Therapeutics, and others.<\/p>\n EGFR NSCLC Market<\/a><\/p>\n EGFR NSCLC Market Insights, Epidemiology, and Market Forecast \u2013 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key EGFR NSCLC companies, including AstraZeneca, Boehringer Ingelheim, Eli Lilly, Hansoh Pharmaceutical, Johnson & Johnson Innovative Medicine, Pfizer, Cullinan Oncology, Taiho Pharmaceutical, ArriVent Biopharma, Black Diamond Therapeutics, Daiichi Sankyo, Akeso Biopharma, Summit Therapeutics, and others.<\/p>\n EGFR Inhibitors Market<\/a><\/p>\n EGFR Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast \u2013 2036 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key EGFR inhibitors companies, including Cullinan Oncology, Taiho Pharma, ArriVent BioPharma, Akeso Biopharma, Summit Therapeutics, Pfizer, Daiichi Sankyo, AstraZeneca, Merck, Kelun-Biotech, CSPC Pharmaceutical, Shanghai JMT-Bio, Bristol-Myers Squibb, AbbVie, Lantern Pharma, Wayshine Biopharm, Teligene US, Genprex, J Ints Bio, Black Diamond Therapeutics, BlossomHill Therapeutics, Scorpion Therapeutics, Pierre Fabre, Antares Therapeutics, A2 Biotherapeutics, BioNTech, Dragonfly Therapeutics, Merus, DualityBio, ORIC Pharmaceuticals, BeOne Medicines (formerly BeiGene), Dizal Pharmaceutical, Jiangsu Hansoh Pharmaceutical, Boehringer Ingelheim, Pfizer, Johnson & Johnson Innovative Medicine, Yuhan Corporation, Eli Lilly and Company, and others.<\/p>\n Antibody Drug Conjugates Market<\/a><\/p>\n Antibody Drug Conjugates Market Size, Target Population, Competitive Landscape & Market Forecast \u2013 2036 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key ADCs companies, including ImmunoGen, Daiichi Sankyo, AstraZeneca, Seagen, Sorrento Therapeutics, Inc., Mythic Therapeutics, Merck KGaA, NBE-Therapeutics AG, Gilead Sciences, Regeneron Pharmaceuticals, Kirilys Therapeutics Inc., Tanabe Research Laboratories USA Inc, Sutro Biopharma, Inc., OBI Pharma, Inc, MediLink Therapeutics (Suzhou) Co., Ltd., TORL Biotherapeutics, LLC, Ambrx, Inc., and others.<\/p>\n About\u00a0DelveInsight<\/p>\n DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.\u00a0Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform\u00a0PharmDelve.<\/p>\n Contact Us<\/p>\n Shruti Thakur \u00a0
\n In June 2026, MAIA Biotechnology announced the activation of Winship Cancer Institute of Emory University as the third U.S. site in its Phase 2 THIO-101 expansion trial. The study is enrolling patients to assess ateganosine as a third-line therapy for non-small cell lung cancer (NSCLC).
\n In May 2026, Bristol Myers Squibb (BMS) and its partner BioNTech unveiled interim Phase II findings from the global Phase II\/III ROSETTA Lung-02 trial (NCT06712316) at ASCO 2026, evaluating the PD-L1\/VEGF bispecific antibody pumitamig in combination with chemotherapy as a first-line treatment for patients with previously untreated non-small cell lung cancer (NSCLC).
\n In May 2026, Nuvation Bio entered into a strategic collaboration with Thermo Fisher Scientific for the U.S.-based manufacturing of ibtrozi, an investigational drug targeting ROS1-positive non-small cell lung cancer (NSCLC).
\n In May 2026, Innovent Biologics, Inc. reported preliminary findings from a proof-of-concept (PoC) clinical study evaluating its first-in-class global PD-1\/IL-2\u03b1-biased bispecific fusion protein, IBI363 (Takeda R&D code: TAK-928), in combination with chemotherapy for the first-line treatment of advanced non-small cell lung cancer (NSCLC). The results were presented at the 2026 ASCO Annual Meeting.
\n In May 2026, Dizal shared findings from two non-small cell lung cancer (NSCLC) studies at the 2026 ASCO Annual Meeting. One study highlighted the investigational fourth-generation EGFR tyrosine kinase inhibitor (TKI), DZD6008, in previously treated NSCLC patients harboring EGFR C797X mutations after disease progression on third-generation EGFR TKIs, with results presented during an oral session. The second study reported outcomes of golidocitinib, a selective JAK1 inhibitor, used in combination with an anti-PD-1 antibody as a first-line therapy for patients with PD-L1-positive advanced NSCLC lacking driver mutations.<\/p>\n
\n Gender-specific Cases of NSCLC\u00a0
\n Age-specific Cases of NSCLC\u00a0
\n Total Incident Cases of NSCLC by Histology\u00a0
\n Total Incident Cases of NSCLC\u00a0 by Stage\u00a0
\n Total Incident Cases of NSCLC by Genetic Mutations\/Biomarkers\u00a0
\n Patient Seeking Treatment for NSCLC\u00a0
\n Line-wise Treated Cases of Metastatic NSCLC<\/p>\n
\n Non-small Cell Lung Cancer Therapeutics Market Size
\n Non-small Cell Lung Cancer Pipeline Analysis
\n Non-small Cell Lung Cancer Market Size and Trends
\n Non-small Cell Lung Cancer Market Opportunity
\n Non-small Cell Lung Cancer Market Unmet Needs
\n KOL’s Views on Non-small Cell Lung Cancer
\n Non-small Cell Lung Cancer Market Access and Reimbursement<\/p>\n
info@delveinsight.com<\/a>
+14699457679
www.delveinsight.com<\/a>\u00a0<\/p>\n
![\"\"](\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=EN96953&Transmission_Id=202607021031PR_NEWS_EURO_ND__EN96953&DateId=20260702\")
<\/p>\n","protected":false},"excerpt":{"rendered":"The non-small cell lung cancer market is experiencing robust growth, driven by the increasing incidence of lung cancer…\n","protected":false},"author":2,"featured_media":75145,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[20662],"tags":[11153,34068,30243],"class_list":["post-75144","post","type-post","status-publish","format-standard","has-post-thumbnail","category-astrazeneca","tag-astrazeneca","tag-delveinsight-business-research","tag-llp"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@UnitedKingdom\/116851020132048082","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/75144","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/comments?post=75144"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/75144\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media\/75145"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media?parent=75144"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/categories?post=75144"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/tags?post=75144"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}